8-K: Verona Pharma Shareholders Approve $10B Merck Acquisition

Verona Pharma plc shareholders have overwhelmingly approved the proposed $10 billion acquisition by Merck, moving the transaction closer to its expected October 7, 2025 closing.

Summary

• Verona Pharma plc shareholders approved the proposed acquisition by Merck & Co., Inc. (through its subsidiary Vol Holdings LLC) for $107 per American Depositary Share (ADS), valuing the transaction at approximately $10 billion.
• The approval occurred at a Court Meeting and a General Meeting held on September 24, 2025.
• At the Court Meeting, 99.49% in value of Scheme Shares voted were in favor of the Scheme of Arrangement.
• At the General Meeting, 99.51% of votes were cast in favor of the special resolution to amend the Articles of Association and authorize directors to effect the Scheme.
• An advisory, non-binding proposal to approve executive compensation related to the transaction received 81.19% of votes in favor.
• The transaction remains subject to the sanction of the Scheme by the High Court of Justice of England and Wales, with the Court Sanction Hearing scheduled for October 6, 2025.
• The Effective Date of the Scheme is expected to be October 7, 2025, assuming Court sanction.

Sentiment

Score: 9

Explanation: The sentiment is highly positive for shareholders due to the overwhelming approval of a significant acquisition at a premium price, providing a clear exit strategy and substantial return. The transaction is progressing as expected towards a definitive closing.

Positives

• Shareholders overwhelmingly approved the acquisition, with 99.49% in value of Scheme Shares voting in favor at the Court Meeting and 99.51% of votes cast in favor of the special resolution at the General Meeting.
• The acquisition price of $107 per ADS, representing a total transaction value of approximately $10 billion, provides a significant premium for shareholders.
• A clear and updated timetable for the transaction's completion has been provided, with an expected Effective Date of October 7, 2025, indicating a smooth progression towards closing.

Negatives

• The non-binding advisory vote on executive compensation in connection with the transaction saw 104,385,363 votes against and 6,070,861 withheld, indicating some shareholder dissent on this specific matter.
• Verona Pharma plc will cease to exist as an independent publicly traded entity, leading to the delisting of its shares from Nasdaq.

Risks

• The consummation of the Transaction remains subject to closing conditions, including the sanction of the Scheme of Arrangement by the High Court of Justice of England and Wales.
• There is a risk that competing offers or acquisition proposals could be made, although the current agreement is definitive.
• The possibility exists that various conditions to the consummation of the proposed transaction contained in the Transaction Agreement may not be satisfied or waived.
• Potential effects of disruption from the transactions contemplated by the Transaction Agreement and the impact of the announcement and pendency of the transactions on the company's business.
• Shareholder litigation in connection with the proposed transaction may result in significant costs of defense, indemnification, and liability.
• The company's dependence on the successful commercialization of Ohtuvayre and the uncertain market acceptance of Ohtuvayre as a treatment for COPD.
• Risks related to pharmaceutical product development, including the company's ongoing development of ensifentrine and any other product candidates and combinations, and the uncertainty of clinical success.

Future Outlook

The company anticipates the acquisition by Merck to close on October 7, 2025, following the Court Sanction Hearing scheduled for October 6, 2025. The immediate future outlook is focused on completing the Scheme of Arrangement and the subsequent delisting of shares.

Management Comments

• David Zaccardelli, Pharm. D., President and Chief Executive Officer, signed the Current Report on Form 8-K on behalf of Verona Pharma plc, indicating official endorsement of the reported events.

Industry Context

This acquisition reflects a broader trend in the biopharmaceutical industry where larger pharmaceutical companies like Merck acquire specialized firms with promising assets, particularly in areas like respiratory diseases, to expand their pipelines and market presence. It signifies consolidation and strategic portfolio enhancement within the sector.

Corporate Governance

Stakeholder Impact

• Shareholders: Will receive $107 per ADS in cash, representing a significant return on investment and a clear exit from their holdings.
• Employees: The acquisition by Merck will likely lead to integration into a larger organizational structure, potentially impacting roles, responsibilities, and career opportunities.
• Customers: Potential for broader reach or integration of Verona Pharma's respiratory disease therapies (e.g., Ohtuvayre, ensifentrine) under Merck's global commercialization and development capabilities.

Next Steps

• The Court Sanction Hearing for the Scheme of Arrangement is scheduled for October 6, 2025.
• The last day for dealings in ADSs on Nasdaq by investors is October 6, 2025.
• The Scheme Record Time is 6:00 p.m. (U.K. Time) on October 6, 2025.
• Formal suspension by Nasdaq of dealings in ADSs is expected on October 7, 2025.
• The Effective Date of the Scheme of Arrangement is expected to be October 7, 2025.
• The last day for settlement of trades of Verona ADSs on Nasdaq is October 7, 2025.
• Payment of consideration in respect of Depositary Shares to the Depositary is expected by October 8, 2025.
• Dispatch of cheques and crediting of CREST accounts for the consideration in respect of Remnant Shares is expected by October 14, 2025.

Key Dates

Recommendation

The acquisition by Merck at a fixed price of $107 per ADS is proceeding towards a definitive closing date. For current shareholders, the optimal action is to sell their shares on the market before the last day of trading (October 6, 2025) or hold them to receive the cash consideration upon the transaction's completion, as there is no further upside potential beyond the agreed acquisition price. Selling on the market may offer slightly faster liquidity.

Keywords

Verona Pharma, Merck, Acquisition, Biopharmaceutical, Respiratory Diseases, M&A, VRNA, MRK, Scheme of Arrangement, Shareholder Vote, COPD, Ohtuvayre, Ensifentrine